<DOC>
	<DOCNO>NCT01212627</DOCNO>
	<brief_summary>The main purpose study evaluate best dose , safety side effect ridaforolimus give cetuximab patient head neck , lung colon cancer progress initial therapy . A second purpose study gain preliminary information whether combination ridaforolimus cetuximab helpful treat patient advanced head neck cancer</brief_summary>
	<brief_title>Ridaforolimus With Cetuximab Patients With Advanced Head Neck Cancer , Non-Small Cell Lung Cancer Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically advance head neck cancer , NSCLC colorectal cancer ( wildtype KRAS ) curable option progress least one regimen advance disease . Once final dose level determine , patient advance lung cancer fail least one line chemotherapy eligible accrue 13 patient expand cohort . *** As July 7 , 2011 final dose level determine next cohort patient advance lung cancer enrolled** Patient measurable disease protocolspecific RECIST criterion . A minimum 4 week elapse prior chemotherapy day 1 study treatment . A minimum 14 day elapse since prior kinase inhibitor therapy radiotherapy , minimum 4 week elapse since prior bevacizumab . No prior exposure mTOR inhibitor . Prior cetuximab exposure allow . ECOG performance status 01 Required initial lab value : Hemoglobin ≥9.0 g/dL , absolute neutrophil count ≥1,500/mm3 , platelet count ≥100,000/mm3 , total bilirubin ≤1.5 time upper limit normal , AST ALT &lt; 3 time upper limit normal , serum albumin ≥2.5 g/dL , serum cholesterol ≤350 mg/dL , triglyceride ≤400 mg/dL , creatinine &lt; 1.5 time upper limit normal , calculated creatinine clearance ≥50 ml/min . Age ≥18 year Those childbearing potential must agree use effective method contraception Patients must ability understand give write informed consent Exclusion criterion : Patient known active brain metastasis . Patients previously treat brain metastasis stable &gt; 3months eligible current brain MRI ( within 28 day day 1 study treatment ) show edema evidence progression compare prior study least 3 month ago . Patient currently participate participate study investigational anticancer treatment device within 30 day 5 half life investigational compound ( whichever great ) initial dose study drug . Patient previously receive rapamycin rapamycin analog , include ridaforolimus , everolimus , temsirolimus . Patient receive corticosteroid administer dos great use normal replacement therapy . Patient history prior invasive malignancy except basal cell carcinoma skin within past two year deem low risk recurrence treat physician . Patient know severe hypersensitivity macrolide antibiotic ( ie : clarithromycin , erythromycin , azythromycin ) . Patient NYHA Class III IV congestive heart failure significant history cardiac disease include : myocardial infarction within last 6 month ; ventricular arrhythmia acute congestive heart failure within last 3 month ; uncontrolled angina uncontrolled hypertension . Patient known HIV positive know history Hepatitis B C. Patient psychiatric disorder would interfere cooperation requirement trial , regular user illicit drug ( include `` recreational use '' ) , recent history ( within last year ) drug alcohol dependence . Patient pregnant breastfeeding , expect conceive within project duration study . Patient active infection require intravenous antibiotic . Patient requirement concurrent treatment medication strong inducer inhibitor cytochrome P450 ( CYP3A ) ( see Appendix ) . Patients discontinue medication least 2 week prior first dose ridaforolimus . Concomitant medication metabolize CYP3A allow ( e.g. , simvastatin atorvastatin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>